Burning Rock’s US stock surges after $223m IPO prices high
Burning Rock Biotech, a Chinese cancer treatment firm, raised $222.8m from its US listing last Friday. The issuer's stock soared nearly 50% on its debut, after the IPO was priced above the initial guidance.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: